27 Jun 2025 • In the VISIBLE trial (Cohort B), guselkumab significantly improved outcomes in managing moderate to severe scalp psoriasis in patients with skin of color.

At week 16, 68.4% of patients on guselkumab experienced near-clear scalp (ss-IGA 0/1) vs. 11.5% on placebo, and 65.8% achieved ≥90% improvement in Psoriasis Scalp Severity Index vs. 3.8%.

Patients on gulsekumab also had superior complete scalp clearance (ss-IGA 0; 57.9% vs. 3.8%), quality of life improvement (-9.7 vs. -2.2), symptom relief (-44.8 vs. -8.3), and itch reduction (69.4% vs. 24%).

Benefits were sustained through week 48, with infections being the most common adverse event (14.8% vs. 3.7%).

Source: JAMA Network | Read Full Story